Viewing nowBarretan Tablet 160 mg (Valsartan)
Valsartan 160mg
Tablet · Prescription medication
CTC Bio, Co., Ltd.

MFDS item code 201507764 · Approved 2015.11.19 · Insurance code 669501590
Treatment of essential hypertension; reduction of the risk of death after myocardial infarction; treatment of heart failure
This medicine is used for the treatment of essential hypertension and is also helpful for heart failure patients who are intolerant to ACE inhibitors. Additionally, it has the effect of reducing the risk of mortality in clinically stable patients with left ventricular dysfunction after myocardial infarction. Therefore, it is used to control blood pressure, improve symptoms of heart failure, and increase survival after myocardial infarction.
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended oral dose is 80 mg of valsartan once daily. The blood pressure-lowering effect appears gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be administered concomitantly. If additional blood pressure reduction is required, the dose may be increased to a maximum of 320 mg per day. 2) Elderly patients (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients receiving dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily, and the dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, reduction of the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily, followed over several weeks by dose increases, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or greater. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or patients receiving dialysis because there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, it is preferable that the daily dose of this medicine not exceed 80 mg. If a dose of 80 mg or more per day is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Children and adolescents under 18 years of age: Safety and efficacy have not been established. Children and adolescents under 18 years of age: Safety and efficacy have not been established.
This drug can cause serious harm to the fetus and newborn if taken during pregnancy, particularly in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. Patients with known allergy to this drug, women who are pregnant or may become pregnant, nursing women, patients with severe liver or kidney disease, and those with a history of hereditary angioedema should not take this medication. Elderly patients, those with high potassium levels in the blood, patients with impaired liver function, heart valve disease or cardiovascular diseases, and patients with very low blood pressure should be careful when taking this drug. Since this medicine lowers blood pressure, dizziness or fainting may occur due to sudden drops in blood pressure when first taken, so caution is necessary. Patients with heart failure or post-myocardial infarction may experience changes in kidney function, so regular kidney function tests should be performed, and consultation with a specialist is required when taking this medication along with other antihypertensive drugs. This drug can increase blood potassium levels, so careful monitoring of serum potassium concentrations is necessary when taken with potassium supplements or potassium-sparing diuretics. Additionally, taking this drug with non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the antihypertensive effect or worsen kidney function, so caution is advised. While taking this drug, side effects such as headache, dizziness, fatigue, cough, and indigestion may occur, and if severe allergic reactions, angioedema, or signs of kidney dysfunction appear, medical attention should be sought immediately. Women who are pregnant or planning to become pregnant should not take this medication, and nursing women are also advised to avoid it. This medication should not be used in children and adolescents under 18 years of age, as its safety and efficacy have not been fully established in this population. In case of overdose, severe hypotension or altered consciousness may occur, requiring immediate emergency care, and it should be kept out of reach of children.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, it is recommended to store it in a cool place below 30 degrees Celsius to maintain its effectiveness.
Oval film-coated tablet in orange color with a gray hue
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 160mg
Tablet · Prescription medication
CTC Bio, Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.